SERNOVA SHARES to Commence Trading on TSX On June 2, 2022
 | |||||||||
 |  |  |  | ||||||
London, Ontario – TheNewswire - June 1, 2022 – Sernova Corp. (TSXV:SVA); (OTC:SEOVF); (FSE/XETRA:PSH), a clinical-stage company and leader in regenerative medicine cell therapeutics, is pleased to announce that its common shares have been approved for listing on the Toronto Stock Exchange (the "TSX") and will commence trading on the TSX at the opening of market on June 2, 2022. Concurrent with the TSX listing, the common shares of the Company will be delisted from the TSX Venture Exchange.
Shareholders are not required to exchange their share certificates or take any other action in connection with the TSX listing, as there will be no change in the trading symbol or CUSIP for the common shares. The Company will continue to trade its common shares on the OTCQB market in the United States under the symbol "SEOVF", and the Frankfurt exchange under the symbol "PSH".
ABOUT SERNOVA CORP. AND THE CELL POUCH SYSTEM™ PLATFORM FOR CELL THERAPY
Sernova Corp. is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells (i.e., human donor cells, corrected human cells and stem-cell derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin- dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body.
The Cell Pouch™ is a proprietary, scalable, implantable macro- encapsulation device solution designed for the long-term survival and function of therapeutic cells. After implantation, the device incorporates with tissue, forming highly vascularized, native tissue chambers for the transplantation and function of therapeutic cells, that release proteins and hormones as required to treat disease.
The Cell Pouch along with therapeutic cells, has been shown to provide long-term safety and efficacy in small and large animal models of diabetes and has been proven to provide a biologically compatible environment for insulin-producing cells in humans in a Canadian first-in-human study. Sernova is currently conducting a Phase 1/2 clinical trial study at the University of Chicago. Encouraging interim results have been presented at several international scientific conferences.
For more information, please visit www.sernova.com
For further information contact:
Corporate and Investors:
Sernova Corp.
Christopher Barnes
Tel: (519) 858-5126
christopher.barnes@sernova.com
Investors:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
Tel: 212-915-2577
Media:
Elizabeth Miller, MD
LifeSci Communications
Neither the TSXV nor the TSX accepts responsibility for the adequacy or accuracy of this news release.
FORWARD-LOOKING INFORMATION
This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions of Sernova’s management on the date such statements were made, which include our beliefs about the conduct and outcome of clinical trials, and the development of new technologies, cell therapy solutions and or products. The information disclosed represents results from one patient and may not be representative of all study patients or of the final study results. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.